
Carragelose®



Eye drops

Novel ophthalmic solution for lubrication & beyond


- Ophthalmic solution based on Carragelose® with moisturizing and mucoadhesive properties
- Forms a protective barrier on the ocular surface; the moisture film supports the body's natural defense mechanisms
- Can be used as lubricant to prevent further irritation or to provide long-lasting relief for dry eyes

Benefits

- Combines moisturizing with virus- and allergen-blocking properties
- · Outstanding safety profile shown in more than 10 preclinical safety and toxicity studies
- For adults and children 6y+
- Clinically validated, patent-protected & CE-certified
- Sterile, preservative-free, multi-dose container (3.2 mg/ml Carragelose®)

Data¹

Ex-vivo testing on porcine eyes to assess the hydrating potential of Carragelose®




- Porcine eyes dehydrated by exposure to air flow for 6h
- Treatment: repeated instillation of 0.9% NaCl, Carragelose® eye drops or marketed competitor products
- Corneal damage quantified by dye extraction from corneal punches after fluorescein staining

Carragelose® eye drops outperfom marketed products on porcine eyes

Data on file by Marinomed; error bars represent the SEM; statistical analysis done by ANOVA

Clinical study in Spain evaluating the lubricating effectiveness of Carragelose® eye drops in patients affected by mild to moderate dry eye




*ACE = adverse controlled environmental conditions

- 28 dry eye patients treated with eye drops: 28 days, 3x daily, one drop/eye
- Adverse controlled
 environmental conditions:
 23°C, 10% relative humidity and
 airflow to challenge dry eye
 symptoms
- Assessment of difference in dry eye-related symptoms before and after treatment

54%
improvement
of dry eyerelated
symptoms

Mode of Action

Carragelose® (iota-carrageenan) is a high-molecular weight polymer derived from red seaweed. Due to its high water-binding capacity, Carragelose® forms soft gels in the presence of water, creating a protective and moisturizing barrier on mucosal surfaces such as the nasal or ocular surface. This barrier has been shown to prevent both viruses and allergens from interacting with the mucosal surface, thereby being effective in preventing and treating viral respiratory infections and allergic indications. Furthermore, the moisturizing film created by Carragelose® has lubricating properties that provide relief for dry eyes.



Alternative to aluronic acid with additional virus- and allergen-blocking <u>properties</u>

Partnering opportunities

- Medical device class IIa valid CE-certificate under transition period until 2028 (MDD), switch to MDR on track
- Approved claims: Lubricant to prevent further irritation or to relieve dryness of the eye
- Might be first causative treatment for adenoviral keratoconjunctivitis
- First partnership for Austria in place
- Classical license deal with downpayment, milestones and royalties
- Global and territorial license available
- Private label possible
- Other Carragelose® products available for partnering: nasal & throat sprays, lozenges

About Marinomed Biotech AG

Marinomed Biotech AG is an Austrian, science-based biotech company with globally marketed therapeutics and a growing development pipeline. The Company focuses on the development of innovative products based on two patent-protected technology platforms, Marinosolv® and Carragelose®. Marinomed is listed on the Vienna Stock Exchange (VSE: MARI).



For more information, please contact our Business Development team: E-Mail: bd@marinomed.com Tel.: +43 2262 90300 www.carragelose.com

Follow us on

@Marinomed Biotech AG



@Marinomed_AG







Marinomed Biotech AG, www.marinomed.com Hovengasse 25, 2100 Korneuburg, Austria